PON2 and chronic myelogenous leukemia, BCR-ABL1 positive: This evident role in cell death resistance may explain why PON2 levels in pediatric acute lymphatic leukemia (ALL) and chronic myeloic leukemia (CML) were associated with poor prognosis and resistance against Imatinib, respectively [27], [28], [29].